坦索罗辛胶囊与多沙唑嗪片治疗良性前列腺增生伴下尿路症状的临床研究

发布时间：2018-05-14 23:04

  本文选题：坦索罗辛胶囊 + 多沙唑嗪片　； 参考：《中国临床药理学杂志》2017年24期

【摘要】：目的观察坦索罗辛胶囊和多沙唑嗪片分别联合酒石酸托特罗定缓释片治疗良性前列腺增生伴下尿路症状患者的临床疗效和安全性。方法将120例患者随机分为对照组60例和试验组60例。对照组予以口服多沙唑嗪4 mg qn和酒石酸托特罗定4 mg qn,4周为1疗程,共治疗3个疗程;试验组予以口服坦索罗辛0.2 mg qn和酒石酸托特罗定4 mg qn,4周为1疗程,共治疗3个疗程。比较2组患者的临床疗效、国际前列腺症状(IPSS)评分、刺激症状评分、最大尿流速(Q_(max))、生活质量评分(QOL)、膀胱过度活动症评分(OABSS)、膀胱过度活动症状以及药物不良反应发生率。结果治疗后,试验组和对照组的总有效率分别为96.67%(58例/60例)和83.33%(50例/60例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的IPSS评分分别为(14.08±4.52),(17.15±4.34)分,刺激症状评分分别为(4.47±1.11),(5.77±1.10)分,Q_(max)分别为(14.15±1.72),(13.21±2.16)mL·s~(-1),QOL评分分别为(1.38±0.99),(3.27±1.39)分,OABSS评分分别为(8.08±2.12),(13.83±4.37)分,日间排尿次数分别为(7.52±2.21),(8.68±2.00)次,夜尿次数分别为(1.40±0.76),(2.48±1.48)次,急迫性尿失禁次数分别为(1.00±0.55),(1.90±0.35)次,尿急次数分别为(2.58±1.08),(4.53±0.98)次,差异均有统计学意义(均P0.05)。试验组和对照组药物不良反应发生率分别为5.00%(3例/60例)和5.00%(3例/60例),差异无统计学意义(P0.05)。结论坦索罗辛联合酒石酸托特罗定治疗良性前列腺增生伴下尿路症状患者的临床疗效优于多沙唑嗪联合酒石酸托特罗定方案,安全性高。
[Abstract]:Objective to observe the clinical efficacy and safety of tansoroxin capsule and doxazosin tablet combined with tolterodine tartrate sustained-release tablets in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms. Methods 120 patients were randomly divided into control group (n = 60) and experimental group (n = 60). The control group received oral administration of doxazosin 4 mg QN and tolterodine tartrate 4 mg QN for 4 weeks for 3 courses of treatment, while the experimental group received oral administration of tamsoloxin 0.2 mg QN and tolterodine tartrate 4 mg QNX for 4 weeks as a course of treatment. There were 3 courses of treatment. The clinical efficacy, international prostate symptom IPSS score, stimulation symptom score, maximal urinary flow rate, QOL score, bladder hyperactivity symptom and incidence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 96.6767 / 60 and 83.33 / 50 / 60, respectively. The difference was statistically significant (P 0.05). 娌荤枟鍚，

本文编号：1889850